RARITAN - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumabi in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.1,2

The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P

(C) 2020 Electronic News Publishing, source ENP Newswire